(NMRA) Neumora Therapeutics - Ratings and Ratios

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions. The companys lead candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor antagonist currently in Phase 3 clinical trials for major depressive disorder. Its pipeline also includes NMRA-511, which is in Phase 1 clinical trials for agitation associated with Alzheimers disease, and NMRA-266, currently in Phase 1 trials for schizophrenia and other neuropsychiatric disorders. Preclinical programs include NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor) for amyotrophic lateral sclerosis, NMRA-NLRP3 for neurodegenerative conditions, and NMRA-GCase for Parkinsons disease. The company, formerly known as RBNC Therapeutics, Inc., was renamed Neumora Therapeutics, Inc. in October 2021 and is headquartered in Watertown, Massachusetts.

From a technical perspective, NMRA stock is currently trading at $1.56, below its 20-day SMA of $1.75, with resistance levels at 17.5, 14.7, 11.9, and 9.8. The stock exhibits an average 20-day volume of 1,587,156 shares and an ATR of 0.42, indicating moderate volatility. Fundamentally, the company has a market cap of $290.81M, a P/B ratio of 0.86, and an RoE of -91.57, reflecting significant R&D investments without current profitability. Over the next three months, NMRA is expected to face resistance at its 20-day SMA of $1.75, with potential downside supported by its 50-day SMA of $3.91 and 200-day SMA of $9.53. The stocks trajectory will likely depend on clinical trial outcomes and pipeline advancements.